Clinigen Group PLC (CLIN) Receives Consensus Rating of “Buy” from Brokerages

Shares of Clinigen Group PLC (LON:CLIN) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is GBX 1,222.17 ($16.89).

Several research analysts recently weighed in on the company. N+1 Singer reaffirmed a “buy” rating and set a GBX 1,225 ($16.92) target price on shares of Clinigen Group in a research note on Wednesday, November 29th. Peel Hunt reiterated a “buy” rating and issued a GBX 1,350 ($18.65) price target on shares of Clinigen Group in a research report on Thursday, February 1st. Berenberg Bank began coverage on Clinigen Group in a research report on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.58) price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,360 ($18.79) price target on shares of Clinigen Group in a research report on Tuesday, November 7th. Finally, Numis Securities reiterated an “add” rating and issued a GBX 1,208 ($16.69) price target on shares of Clinigen Group in a research report on Wednesday, January 17th.

Clinigen Group (LON CLIN) opened at GBX 1,003 ($13.86) on Thursday. Clinigen Group has a 52 week low of GBX 751.50 ($10.38) and a 52 week high of GBX 1,187 ($16.40). The firm has a market capitalization of $1,240.00 and a PE ratio of 33,433.33.

In related news, insider Chris Rigg sold 4,955 shares of the stock in a transaction on Thursday, November 23rd. The stock was sold at an average price of GBX 1,017 ($14.05), for a total value of £50,392.35 ($69,621.93).

TRADEMARK VIOLATION WARNING: “Clinigen Group PLC (CLIN) Receives Consensus Rating of “Buy” from Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/15/clinigen-group-plc-clin-receives-consensus-rating-of-buy-from-brokerages.html.

Clinigen Group Company Profile

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply